MovDisordV3, PascalFrancis, Corpus, bibRecord, 001284

Placebo Influences on Dyskinesia in Parkinson's Disease

Identifieur interne : 001284 ( PascalFrancis/Corpus ); précédent : 001283; suivant : 001285

Placebo Influences on Dyskinesia in Parkinson's Disease

Auteurs : Christopher G. Goetz ; Eugene Laska ; Christine Hicking ; Philippe Damier ; Thomas Müller ; John Nutt ; C. Warren Olanow ; Olivier Rascol ; Hermann Russ

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0247739

Descripteurs français

Pascal (Inist)
- Dyskinésie, Maladie de Parkinson, Pathologie du système nerveux, Placebo, Sarizotan, Essai clinique.

English descriptors

KwdEn :
- Clinical trial, Dyskinesia, Nervous system diseases, Parkinson disease, Placebo, Sarizotan.

Abstract

Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Placebo Influences on Dyskinesia in Parkinson's Disease`
A11	`01`	`1`		`@1 GOETZ (Christopher G.)`
A11	`02`	`1`		`@1 LASKA (Eugene)`
A11	`03`	`1`		`@1 HICKING (Christine)`
A11	`04`	`1`		`@1 DAMIER (Philippe)`
A11	`05`	`1`		`@1 MÜLLER (Thomas)`
A11	`06`	`1`		`@1 NUTT (John)`
A11	`07`	`1`		`@1 OLANOW (C. Warren)`
A11	`08`	`1`		`@1 RASCOL (Olivier)`
A11	`09`	`1`		`@1 RUSS (Hermann)`
A14	`01`			`@1 Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 1 aut.`
A14	`02`			`@1 New York University School of Medicine @2 New York, New York @3 USA @Z 2 aut.`
A14	`03`			`@1 Nathan Kline Institute @2 Orangeburg, New York @3 USA @Z 2 aut.`
A14	`04`			`@1 Merck KGaA @2 Darmstadt @3 DEU @Z 3 aut. @Z 9 aut.`
A14	`05`			`@1 Centre Hospitalo-universitaire de Nantes, Centre d'Investigation Clinique @2 Nantes @3 FRA @Z 4 aut.`
A14	`06`			`@1 Ruhr University @2 Bochum @3 DEU @Z 5 aut.`
A14	`07`			`@1 Oregon Health Sciences University @2 Portland, Oregon @3 USA @Z 6 aut.`
A14	`08`			`@1 Mount Sinai School of Medicine New York @2 New York @3 USA @Z 7 aut.`
A14	`09`			`@1 Toulouse University Hospital, INSERM Clinical Investigation Center @2 Toulouse @3 FRA @Z 8 aut.`
A20				`@1 700-707`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000173776990100`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 08-0247739`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Placebo @5 09`
C03	`04`	`X`	`ENG`	`@0 Placebo @5 09`
C03	`04`	`X`	`SPA`	`@0 Placebo @5 09`
C03	`05`	`X`	`FRE`	`@0 Sarizotan @2 NK @2 FR @5 10`
C03	`05`	`X`	`ENG`	`@0 Sarizotan @2 NK @2 FR @5 10`
C03	`05`	`X`	`SPA`	`@0 Sarizotán @2 NK @2 FR @5 10`
C03	`06`	`X`	`FRE`	`@0 Essai clinique @5 11`
C03	`06`	`X`	`ENG`	`@0 Clinical trial @5 11`
C03	`06`	`X`	`SPA`	`@0 Ensayo clínico @5 11`
C07	`01`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 37`
C07	`01`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`01`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`02`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`02`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 41`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
N21				`@1 162`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0247739 INIST
ET :	Placebo Influences on Dyskinesia in Parkinson's Disease
AU :	GOETZ (Christopher G.); LASKA (Eugene); HICKING (Christine); DAMIER (Philippe); MÜLLER (Thomas); NUTT (John); OLANOW (C. Warren); RASCOL (Olivier); RUSS (Hermann)
AF :	Rush University Medical Center/Chicago, Illinois/Etats-Unis (1 aut.); New York University School of Medicine/New York, New York/Etats-Unis (2 aut.); Nathan Kline Institute/Orangeburg, New York/Etats-Unis (2 aut.); Merck KGaA/Darmstadt/Allemagne (3 aut., 9 aut.); Centre Hospitalo-universitaire de Nantes, Centre d'Investigation Clinique/Nantes/France (4 aut.); Ruhr University/Bochum/Allemagne (5 aut.); Oregon Health Sciences University/Portland, Oregon/Etats-Unis (6 aut.); Mount Sinai School of Medicine New York/New York/Etats-Unis (7 aut.); Toulouse University Hospital, INSERM Clinical Investigation Center/Toulouse/France (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 5; Pp. 700-707; Bibl. 21 ref.
LA :	Anglais
EA :	Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents.
CC :	002B17; 002B17G
FD :	Dyskinésie; Maladie de Parkinson; Pathologie du système nerveux; Placebo; Sarizotan; Essai clinique
FG :	Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central
ED :	Dyskinesia; Parkinson disease; Nervous system diseases; Placebo; Sarizotan; Clinical trial
EG :	Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease
SD :	Disquinesia; Parkinson enfermedad; Sistema nervioso patología; Placebo; Sarizotán; Ensayo clínico
LO :	INIST-20953.354000173776990100
ID :	08-0247739

Links to Exploration step

Pascal:08-0247739

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Placebo Influences on Dyskinesia in Parkinson's Disease</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="01"><s1>Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name>
<affiliation><inist:fA14 i1="02"><s1>New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Nathan Kline Institute</s1>
<s2>Orangeburg, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name>
<affiliation><inist:fA14 i1="04"><s1>Merck KGaA</s1>
<s2>Darmstadt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation><inist:fA14 i1="05"><s1>Centre Hospitalo-universitaire de Nantes, Centre d'Investigation Clinique</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation><inist:fA14 i1="06"><s1>Ruhr University</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
<affiliation><inist:fA14 i1="07"><s1>Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="09"><s1>Toulouse University Hospital, INSERM Clinical Investigation Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name>
<affiliation><inist:fA14 i1="04"><s1>Merck KGaA</s1>
<s2>Darmstadt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0247739</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0247739 INIST</idno>
<idno type="RBID">Pascal:08-0247739</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001284</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Placebo Influences on Dyskinesia in Parkinson's Disease</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="01"><s1>Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name>
<affiliation><inist:fA14 i1="02"><s1>New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Nathan Kline Institute</s1>
<s2>Orangeburg, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name>
<affiliation><inist:fA14 i1="04"><s1>Merck KGaA</s1>
<s2>Darmstadt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation><inist:fA14 i1="05"><s1>Centre Hospitalo-universitaire de Nantes, Centre d'Investigation Clinique</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation><inist:fA14 i1="06"><s1>Ruhr University</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
<affiliation><inist:fA14 i1="07"><s1>Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="09"><s1>Toulouse University Hospital, INSERM Clinical Investigation Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name>
<affiliation><inist:fA14 i1="04"><s1>Merck KGaA</s1>
<s2>Darmstadt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Dyskinesia</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Sarizotan</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Placebo</term>
<term>Sarizotan</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Placebo Influences on Dyskinesia in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LASKA (Eugene)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HICKING (Christine)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DAMIER (Philippe)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MÜLLER (Thomas)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NUTT (John)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OLANOW (C. Warren)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RUSS (Hermann)</s1>
</fA11>
<fA14 i1="01"><s1>Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Nathan Kline Institute</s1>
<s2>Orangeburg, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Merck KGaA</s1>
<s2>Darmstadt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Centre Hospitalo-universitaire de Nantes, Centre d'Investigation Clinique</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Ruhr University</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Mount Sinai School of Medicine New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Toulouse University Hospital, INSERM Clinical Investigation Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>700-707</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000173776990100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0247739</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Placebo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Placebo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Placebo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Sarizotan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Sarizotan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sarizotán</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>162</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0247739 INIST</NO>
<ET>Placebo Influences on Dyskinesia in Parkinson's Disease</ET>
<AU>GOETZ (Christopher G.); LASKA (Eugene); HICKING (Christine); DAMIER (Philippe); MÜLLER (Thomas); NUTT (John); OLANOW (C. Warren); RASCOL (Olivier); RUSS (Hermann)</AU>
<AF>Rush University Medical Center/Chicago, Illinois/Etats-Unis (1 aut.); New York University School of Medicine/New York, New York/Etats-Unis (2 aut.); Nathan Kline Institute/Orangeburg, New York/Etats-Unis (2 aut.); Merck KGaA/Darmstadt/Allemagne (3 aut., 9 aut.); Centre Hospitalo-universitaire de Nantes, Centre d'Investigation Clinique/Nantes/France (4 aut.); Ruhr University/Bochum/Allemagne (5 aut.); Oregon Health Sciences University/Portland, Oregon/Etats-Unis (6 aut.); Mount Sinai School of Medicine New York/New York/Etats-Unis (7 aut.); Toulouse University Hospital, INSERM Clinical Investigation Center/Toulouse/France (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 5; Pp. 700-707; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents.</EA>
<CC>002B17; 002B17G</CC>
<FD>Dyskinésie; Maladie de Parkinson; Pathologie du   système nerveux; Placebo; Sarizotan; Essai clinique</FD>
<FG>Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Dyskinesia; Parkinson disease; Nervous system diseases; Placebo; Sarizotan; Clinical trial</ED>
<EG>Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease</EG>
<SD>Disquinesia; Parkinson enfermedad; Sistema nervioso patología; Placebo; Sarizotán; Ensayo clínico</SD>
<LO>INIST-20953.354000173776990100</LO>
<ID>08-0247739</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001284 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001284 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0247739
   |texte=   Placebo Influences on Dyskinesia in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Placebo Influences on Dyskinesia in Parkinson's Disease

Placebo Influences on Dyskinesia in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri